HOPA Abstracts & Highlights
At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Dr Seddon provided attendees with an overview of FLT3-mutated AML, including currently available treatments, mechanisms of resistance, and future directions.
At the 2018 Hematology/Oncology Pharmacy Association Annual Conference, Josiah Land, PharmD, BCOP, and Jacob Kettle, PharmD, BCOP, discussed the realities of using PD-L1 as a biomarker in oncology in the front- and second-line settings.
By Chase Doyle
The United States may be in the midst of an opioid epidemic, but the undertreatment of pain remains an issue for patients with cancer.
By Chase Doyle
Although transplantation offers cures or durable remissions for malignancies, relapse is a frequent occurrence in many diseases, and remains a major cause of mortality.
By Chase Doyle
Despite significant progress in stem-cell transplantations over the past decade, graft-versus-host disease (GVHD) remains the leading cause of nonrelapse death in this patient population.
By Chase Doyle
Precision medicine continues to transform oncology, and it is not just the treatments that are changing.
By Chase Doyle
According to the results of a recent survey of hematopoietic stem-cell transplantation (HSCT) professionals, burnout is prevalent across all HSCT disciplines, with pharmacists showing the highest rates of burnout and moral distress.
By Chase Doyle
The overtreatment or undertreatment of patients with cancer can have life-or-death implications.
Patrick J. Medina, PharmD, BCOP, is Professor of Clinical and Administrative Sciences at the University of Oklahoma College of Pharmacy in Tulsa.